Public Health Genomics Knowledge Base (v1.2)
About the Genomics & Health Impact Weekly Scan
This weekly update features emerging roles of human genomics, testing and interventions in a wide variety of noncommunicable diseases across the life span, including, birth defects, newborn screening, reproductive health, childhood diseases, cancer, chronic diseases, pharmacogenomics, family health history, guidelines and recommendations. The weekly sweep also includes news, reviews, commentaries, tools and databases.
Human Genomics across the Lifespan
Birth Defects and Child Health
- Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study
CA Parkinson et al, PLOS Medicine, December 20, 2016
- Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials
FA Sinicrope et al, JAMA Oncology, December 22, 2016
- Study Finds No Safe Level of Smoking
NIH Director Blog, December 13, 2016
- The Angelina Effect: The Power And Perils Of Celebrity Cancer Stories
C Goldberg, WBUR, December 16, 2016
- Circulating Tumor DNA May Serve as a Prognostic Marker in Pancreatic Cancer
J Cavallo, ASCO Post, December 20, 2016
- Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer.
Pearlman Rachel et al. JAMA oncology 2016 Dec
- Universal Genetic Testing for Younger Patients With Colorectal Cancer.
Vilar Eduardo et al. JAMA oncology 2016 Dec
- When Genetic Tests Disagree About Best Option For Cancer Treatment
NPR, December 16, 2016
- Circulating tumor DNA technology: the future of cancer management?
L Blackburn, PHG Foundation, December 20, 2016
- Molecular Markers Beyond Microsatellite Instability for Assessing Prognosis in Early-Stage Colorectal Cancer : What Happens at Relapse?
AS Bianchi. JAMA Oncology, December 22, 2016
- A new type of molecular medicine may be needed to halt cancers
The Economist, December 17, 2016
- Genetic testing in a gynaecological oncology care in developing countries-knowledge, attitudes and perception of Nepalese clinicians.
Pokharel Hanoon P et al. Gynecologic oncology research and practice 2016 312
- Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany.
Schremser Katharina et al. PharmacoEconomics 2015 Nov 33(11) 1215-28
- Toward a Shared Vision for Cancer Genomic Data.
Grossman Robert L et al. The New England journal of medicine 2016 Sep 375(12) 1109-12
- A Precision Medicine Approach to Clinical Trials.
Rubin Rita et al. JAMA 2016 Nov 316(19) 1953-1955
- Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer.
Antonucci Ivana et al. Journal of human genetics 2016 Dec
- Clinical challenges associated with universal screening for Lynch Syndrome associated endometrial cancer.
Bruegl Amanda et al. Cancer prevention research (Philadelphia, Pa.) 2016 Dec
- Previvors' Uncertainty Management Strategies for Hereditary Breast and Ovarian Cancer.
Dean Marleah et al. Health communication 2016 Dec 1-9
Disclaimer: Articles listed in Health Impact Weekly Scan are selected by the CDC Office of Public Health Genomics to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
Genomics in Practice
- Precision Medicine, Genomics, and Public Health
DK ARnett et al, Diabetes Care, December 2016
- Use of big data for drug development and for public and personal health and care
L Leyens et al, Genetic Epidemiology, NOvember 2016
- Precision Medicine: What Does it Mean for Your Health?
- 2016: The year of precision public health
Muin J. Khoury, Blog Post, CDC December 14, 2016
- Learning Health Systems as Facilitators of Precision Medicine.
Ramsey Laura B et al. Clinical pharmacology and therapeutics 2016 Dec
- Bridging the Gap from Bench to Bedside--An Informatics Infrastructure for Integrating Clinical, Genomics and Environmental Data (ICGED).
et al. Studies in health technology and informatics 2015 2161054
- The value of genetic testing: beyond clinical utility.
Lerner Barbara et al. Genetics in medicine : official journal of the American College of Medical Genetics 2016 Dec
- A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level models.
Degeling K et al. Expert review of pharmacoeconomics & outcomes research 2016 Dec
No hay comentarios:
Publicar un comentario